Table 5.

Characteristics and outcome of responding patients

WHO classification	Marrow blasts, %	Karyotype	Clinical response	Time to relapse, mo*	Survival time, mo†
AML without maturation (M1)	35	Pretreatment (no follow-up available): 46,XX,del(5)(q31q33)[14]/46,XX[6]	CRi	2.8	15.1 (died)
AML otherwise categorized	90	Pretreatment: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[5]/54∼55,sl,-der(17)t(17;18), +17,+18, +20,+21,-22,-marx2[cp12]	CRi	0.9	2.8 (died)
		Follow-up: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[2]/54,sl,-mar[4]/46,XY[12]
AML otherwise categorized	80	Pretreatment (no follow-up available): 90–92, XXYY,del(5)(q13q33),-7,+13,+13,der(15) t(9;15)(q12;p11.2),-21,-21, +mar1, +mar2[6]/ 47,XY,+9[2]/46,XY[12]	CR	13.8 (no report of relapse)	15.6 (died)
AML otherwise categorized	27	Pretreatment: 44,XY,del(1)(p36.1),del(5) (q13q33),-7,-10,del(12)(p11.2p12),-20, +mar[11]/44,sl,del(11) (q14q23)[3]/46,XY[6]	CR	5.3	6.7 (alive)
		Follow-up: 46,XY[20] (only 1 process, inadequate for interpretation)
AML with multilineage dysplasia	45	Pretreatment (no follow-up available): 46,XX,del(5)(q15q33)[15]/46,XX[5]	PR	20.2 (no report of relapse)	23.6 (alive)

^*Time to relapse in months was measured from date of response until date of relapse or last contact.

^†Survival time in months was measured from time of study entry until date of death or last contact.